<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>International Journal of Radiation Research</title>
<title_fa>نشریه پرتو پژوه</title_fa>
<short_title>Int J Radiat Res</short_title>
<subject>Basic Sciences</subject>
<web_url>http://ijrr.com</web_url>
<journal_hbi_system_id>79</journal_hbi_system_id>
<journal_hbi_system_user>journal79</journal_hbi_system_user>
<journal_id_issn>2322-3243</journal_id_issn>
<journal_id_issn_online>2345-4229</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.61882/ijrr</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1402</year>
	<month>10</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2024</year>
	<month>1</month>
	<day>1</day>
</pubdate>
<volume>22</volume>
<number>1</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Stereotactic radiotherapy for brain metastases in patients with non-small cell lung cancer: CyberKnife-M6 experience</title>
	<subject_fa>Radiation Biology</subject_fa>
	<subject>Radiation Biology</subject>
	<content_type_fa>تحقيق بديع</content_type_fa>
	<content_type>Original Research</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;font-size:10pt&quot;&gt;&lt;span style=&quot;text-justify:newspaper&quot;&gt;&lt;span style=&quot;text-kashida-space:50%&quot;&gt;&lt;span style=&quot;line-height:119%&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;Background&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;We assessed local control and survival in non-small cell lung cancer (NSCLC) patients with limited brain metastases (BM) who underwent stereotactic radiotherapy (SRT) using the CyberKnife-M6 (CK-M6) system as well as the treatment efficacy. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;Materials and Methods: &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;Twenty NSCLC patients with 40 BM were treated between 2018 and 2020. Median age was 61 years (46-80 years). Surgery was performed for nine lesions in eight cases. Median lesion size was 10 mm (2&amp;ndash;38 mm). Resection cavities and intact metastases contoured as gross target volume. Planning target volume (PTV) was created with a margin of 0&amp;ndash;2 mm. A median of 18 Gy (18&amp;ndash;20 Gy) in one fraction was applied to 19 lesions, and 25 Gy/5 fractions (24&amp;ndash;30 Gy/3&amp;ndash;6 fx) to 21 lesions. Median treatment time was 20 min (13&amp;ndash;35 min). &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;Results: &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;The median follow-up duration was nine months (1&amp;ndash;15 months) in March 2021. Prescription isodose covering 95% of PTV was 85,9% (80% &amp;ndash;92,7%). During the follow-up, local and intracranial control rates in evaluated patients were 88% (15/17) and 70,5% (12/17), respectively. Asymptomatic radionecrosis was observed in 23.5% (4/17) of patients at a median of 8 months (6&amp;ndash;12 months). The median survival was 13 months (1&amp;ndash;25 months). In univariate analysis, factors positively affecting survival were Karnofsky performance status, RPA, and DS-GPA classification (p &lt; 0,05). &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;Conclusion: &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-GB&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span style=&quot;language:en-GB&quot;&gt;Promising local control and survival in patients and treatment time demonstrated that CK-M6 based SRT was effective, safe and comfortable in the treatment of NSCLC with BM.&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;/div&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>brain metastases, cyberknife-M6, stereotactic radiotherapy, efficacy.</keyword>
	<start_page>117</start_page>
	<end_page>124</end_page>
	<web_url>http://ijrr.com/browse.php?a_code=A-10-1-1146&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>S. </first_name>
	<middle_name></middle_name>
	<last_name>Sarihan</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>ssarihan@uludag.edu.tr</email>
	<code>7900319475328460028949</code>
	<orcid>7900319475328460028949</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Bursa Uludag University, Faculty of Medicine, Department of Radiation Oncology, Bursa, Turkey</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>S.G. </first_name>
	<middle_name></middle_name>
	<last_name>Tunc</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460028950</code>
	<orcid>7900319475328460028950</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Bursa Uludag University, Faculty of Medicine, Department of Radiation Oncology, Bursa, Turkey</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Z.K. </first_name>
	<middle_name></middle_name>
	<last_name>Irem</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460028951</code>
	<orcid>7900319475328460028951</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Bursa Uludag University, Faculty of Medicine, Department of Radiation Oncology, Bursa, Turkey</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>A. </first_name>
	<middle_name></middle_name>
	<last_name>Kahraman</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460028952</code>
	<orcid>7900319475328460028952</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Bursa Uludag University, Faculty of Medicine, Department of Radiation Oncology, Bursa, Turkey</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
